Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?
| Authors | |
|---|---|
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | CURRENT ATHEROSCLEROSIS REPORTS |
| MU Faculty or unit | |
| Citation | |
| Web | https://link.springer.com/article/10.1007/s11883-023-01166-3 |
| Doi | http://dx.doi.org/10.1007/s11883-023-01166-3 |
| Keywords | Heart failure; Dyslipidemia; Lipid lowering therapy; Statins; PCSK9 inhibitors |
| Description | Purpose of ReviewAn evidence for lipid lowering therapy in heart failure is briefly summarized in this review.Recent FindingsHeart failure therapy is based on recent guidelines for diagnosis and treatment of acute and chronic heart failure. The question of the importance of hypolipidemic treatment in heart failure remains insufficiently answered. We still rely only on results of two randomized controlled trials that did not show significant benefit of statins on mortality in these patients. In contrast, some meta-analysis, prospective or retrospective cohorts, found some positive effects of this therapy. Recently, the role of inflammation and the possibility of its influence by hypolipidemics have been discussed. PCSK9 inhibitors, new lipid lowering drugs, are very effective in LDL-cholesterol lowering and atherosclerotic cardiovascular diseases prevention. The role of PCSK9 inhibitors in heart failure treatment is investigated.SummaryBased on current knowledge, hypolipidemics are not generally recommended in heart failure therapy, unless there is another indication for their use. |
| Related projects: |